iNtRON Biotechnology Inc (048530.KQ) stock: key figures, P/E, revenue and dividend

Health Care · Biotechnology · South Korea · ISIN KR7048530000

Price
2,825.00 KRW
Market cap
87.27 bn KRW
P/E (2025)
–
P/S (2025)
15.20
Dividend yield
0.00 %
Net margin
-156.06 %
Return on equity (ROE)
-12.82 %
Return on assets (ROA)
-12.05 %

iNtRON Biotechnology Inc financials

Fiscal year20242025
Revenue6.42 bn KRW5.74 bn KRW
Gross profit3.74 bn KRW3.10 bn KRW
Operating income-5.24 bn KRW-7.90 bn KRW
EBIT-2.98 bn KRW-8.94 bn KRW
Net income-2.59 bn KRW-8.96 bn KRW
Diluted EPS – continuing operations-81.03 KRW-290.00 KRW

Full history since 2012, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About iNtRON Biotechnology Inc

iNtRON Biotechnology, Inc. engages in the development of novel biopharmaceutical drugs in South Korea. It develops bacteriophage and endolysin based drugs through itLysin and IMPA platform. The company was founded in 1999 and is headquartered in Seongnam-si, South Korea.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 30.10.2026. Details in the risk notice.